Urapidil in hypercholesterolemic hypertensive patients.

Urapidil in hypercholesterolemic hypertensive patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Urapidil in hypercholesterolemic hypertensive patients. Abstract Text:

The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with alpha-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral alpha-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double-blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides < 350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 +/- 10 vs 49 +/- 7 years), body weight (72 +/- 9 vs 73 +/- 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 +/- 4 vs 119.7 +/- 4 mmHg). The actively treated group significantly decrease BP values from 159/99 +/- 13/2 to 152/90 +/- 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Urapidil in hypercholesterolemic hypertensive patients. Publishing Authors By Initials

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research

PUBMED ID PMID:

MEDLINE DATE:

Urapidil in hypercholesterolemic hypertensive patients. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Blood pressure. Supplement

VOLUME: 4

Page Numbers: 39-44

Journal Abbreviation:

ISSN: 0803-8023

DAY: 26

MONTH: 02

YEAR: 1994

Urapidil in hypercholesterolemic hypertensive patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9300787

Urapidil in hypercholesterolemic hypertensive patients. Keywords Mesh Terms:

KEYWORDS: Piperazines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Urapidil in hypercholesterolemic hypertensive patients. Information

Substance Name: urapidil

Registry Number: 34661-75-1

Grant and Affiliation Information for Urapidil in hypercholesterolemic hypertensive patients.

AFFILIATION: Institute of Internal Medicine, Federico II University, Naples, Italy.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood Press Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Urapidil in hypercholesterolemic hypertensive patients Related Publications

• Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
• Antihypertensive therapy in patients above age 60 with systolic hypertension. A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE).
• Cardiac, renal and vascular complications in the diabetic patient.
• Cardiovascular consequences of hypertension: therapeutic effects on organ damage and on cardiovascular events.
• Cardiovascular effects of afferent renal nerve stimulation.
• Carotid baroreceptor reflex in normotensive and hypertensive subjects.
• Characteristics of an ideal antihypertensive therapy for elderly hypertensives.
• Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage.
• Comparative measurements of immunoreactive renin, plasma renin activity and angiotensin II in human plasma.
• Differences in reflex control of arterial pressure and renin release during head-up tilting in the cat.
• Editing a scientific journal: problems and challenges.
• Evaluation of a new non-invasive semiautomatic blood pressure monitoring device.
• Factors influencing the carotid baroreceptor response to pressure changes in a neck chamber.
• Hemodynamic and neural effects of urapidil and prazosin in essential hypertensives.
• Interplay of sino-aortic reflexes and haemodynamic changes during natural sleep in the cat.
• Introduction.
• Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan.
• Mechanisms of blood pressure variability in man.
• Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study.
• Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atheroscelerosis (ELSA).
• Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients.
• Renin release and renal vasomotor changes during stimulation of the brain stem in the cat.
• Role of the renal nerves in renin release during suprarenal aortic stenosis in cats.
• Target blood pressure in elderly hypertensive patients: how low should you go?
• The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence.
• The sympathetic nervous system in human hypertension.
• Time course of the changes in active and cryoactivatable renin in response to acute stimuli before and after diuretic therapy in man.
• Urapidil in hypercholesterolemic hypertensive patients.
• Value of echocardiographic and ambulatory blood pressure monitoring in hypertension.
• [Not Available.]